ESR2 and prostate carcinoma: Studies demonstrated that decitabine and trichostatin A co-administration potentiated the re-expression of ERβ in breast, ovary, and prostate cancer cell lines, and induced apoptosis, cell differentiation, and growth termination [14, 35].